Looking to expand your partner network with the latest in the field of Protein? Consider joining Inpart's global network for free.
In Depth 22 Oct 2025
PCSK9’s second act: From antibodies to gene editing
With Eli Lilly’s recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.
